EGFR and head and neck squamous cell carcinoma: We sought to compare the effects of dacomitinib with cetuximab, an EGFR inhibitor that is the currently the only FDA-approved targeted therapy for HNSCC treatment and to erlotinib a small molecule EGFR inhibitor not yet FDA approved in HNSCC.